We are analyzing https://link.springer.com/article/10.1007/s10585-008-9172-4.

Title:
Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis | Clinical & Experimental Metastasis
Description:
Osteosclerotic metastases account for 20% of breast cancer metastases with the remainder osteolytic or mixed. In mouse models, osteolytic metastases are dependent on bone resorption for their growth. However, whether the growth of osteosclerotic bone metastases depends on osteoclast or osteoblast actions is uncertain. In this study, we investigate the effects of high and low bone resorption on tumour growth in a mouse model of osteosclerotic metastasis. We implanted human breast cancer, MCF-7, cells into the tibiae of mice. Low and high levels of bone resorption were induced by osteoprotegerin (OPG) treatment or calcium deficient diet respectively. We demonstrate that OPG treatment significantly reduces tumour area compared to vehicle (0.42 ± 0.06 vs. 1.27 ± 0.16 mm2, P < 0.01) in association with complete inhibition of osteoclast differentiation. In contrast, low calcium diet increases tumour area compared to normal diet (0.90 ± 0.30 vs. 0.58 ± 0.20 mm2, P < 0.05) in association with increased osteoclast numbers (84.44 ± 5.18 vs. 71.11 ± 3.56 per mm2 bone lesion area, P < 0.05). Osteoblast surfaces and new woven bone formation were similarly increased within the tumour boundaries in all treatment groups. Tumour growth in this model of osteosclerotic metastasis is dependent on ongoing bone resorption, as has been observed in osteolytic models. Bone resorption, rather than bone formation, apparently mediates this effect as osteoblast surfaces in the tumour mass were unchanged by treatments. Treatment of breast cancer patients through correction of calcium deficiency and/or with anti-resorptive agents such as OPG, may improve patient outcomes in the adjuvant as well as palliative settings.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,625,932 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

bone, cancer, article, pubmed, google, scholar, cas, metastasis, breast, growth, metastases, resorption, tumour, clin, res, model, osteolytic, research, osteoprotegerin, calcium, mouse, osteosclerotic, prostate, zhou, seibel, access, role, privacy, cookies, content, increases, zheng, models, osteoblast, human, opg, treatment, disease, metastatic, rev, mechanisms, osteoblastic, elderly, secondary, hyperparathyroidism, area, publish, search, clinical, osteoclast,

Topics {✒️}

month download article/chapter severe-combined-immunodeficient mouse model modulating age-related increases dietary calcium deficiency urinary pyridinium cross-links experimental bone metastasis human breast cancer full article pdf calcium deficient diet breast cancer metastases osteosclerotic bone metastasis medical research council anzac research institute metastatic bone disease privacy choices/manage cookies european economic area related subjects osteoprotegerin inhibits osteolysis osteotropic breast cancer primary breast cancer guise ta low bone resorption breast cancer patients subsequent bone metastasis potentiates bone metastasis enhances osteoclast formation article zheng intra-tibial growth ongoing bone resorption bone resorption predicts accelerated bone resorption osteoblastic bone metastases serum bone sialoprotein osteolytic bone metastasis microenvironmental support impairs anti-tumor effect anti-tumour actions neoplastic bone involvement hypoxia-driven cancer osteolytic bone metastases woven bone formation growth factor-1 postmenopausal bone loss check access instant access anti-resorptive agents improve patient outcomes cook rj south wales government nude mouse models

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis
         description:Osteosclerotic metastases account for 20% of breast cancer metastases with the remainder osteolytic or mixed. In mouse models, osteolytic metastases are dependent on bone resorption for their growth. However, whether the growth of osteosclerotic bone metastases depends on osteoclast or osteoblast actions is uncertain. In this study, we investigate the effects of high and low bone resorption on tumour growth in a mouse model of osteosclerotic metastasis. We implanted human breast cancer, MCF-7, cells into the tibiae of mice. Low and high levels of bone resorption were induced by osteoprotegerin (OPG) treatment or calcium deficient diet respectively. We demonstrate that OPG treatment significantly reduces tumour area compared to vehicle (0.42 ± 0.06 vs. 1.27 ± 0.16 mm2, P < 0.01) in association with complete inhibition of osteoclast differentiation. In contrast, low calcium diet increases tumour area compared to normal diet (0.90 ± 0.30 vs. 0.58 ± 0.20 mm2, P < 0.05) in association with increased osteoclast numbers (84.44 ± 5.18 vs. 71.11 ± 3.56 per mm2 bone lesion area, P < 0.05). Osteoblast surfaces and new woven bone formation were similarly increased within the tumour boundaries in all treatment groups. Tumour growth in this model of osteosclerotic metastasis is dependent on ongoing bone resorption, as has been observed in osteolytic models. Bone resorption, rather than bone formation, apparently mediates this effect as osteoblast surfaces in the tumour mass were unchanged by treatments. Treatment of breast cancer patients through correction of calcium deficiency and/or with anti-resorptive agents such as OPG, may improve patient outcomes in the adjuvant as well as palliative settings.
         datePublished:2008-04-18T00:00:00Z
         dateModified:2008-04-18T00:00:00Z
         pageStart:559
         pageEnd:567
         sameAs:https://doi.org/10.1007/s10585-008-9172-4
         keywords:
            Breast cancer
            Bone remodelling
            Bone metastasis
            Osteosclerosis
            Dietary calcium
            Osteoprotegerin
            Osteoclasts
            Cancer Research
            Biomedicine
            general
            Oncology
            Hematology
            Surgical Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10585-008-9172-4/MediaObjects/10585_2008_9172_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10585-008-9172-4/MediaObjects/10585_2008_9172_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10585-008-9172-4/MediaObjects/10585_2008_9172_Fig3_HTML.gif
         isPartOf:
            name:Clinical & Experimental Metastasis
            issn:
               1573-7276
               0262-0898
            volumeNumber:25
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Netherlands
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yu Zheng
               affiliation:
                     name:University of Sydney
                     address:
                        name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hong Zhou
               affiliation:
                     name:University of Sydney
                     address:
                        name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Colette Fong-Yee
               affiliation:
                     name:University of Sydney
                     address:
                        name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:James R. K. Modzelewski
               affiliation:
                     name:University of Sydney
                     address:
                        name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Markus J. Seibel
               affiliation:
                     name:University of Sydney
                     address:
                        name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Colin R. Dunstan
               affiliation:
                     name:University of Sydney
                     address:
                        name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis
      description:Osteosclerotic metastases account for 20% of breast cancer metastases with the remainder osteolytic or mixed. In mouse models, osteolytic metastases are dependent on bone resorption for their growth. However, whether the growth of osteosclerotic bone metastases depends on osteoclast or osteoblast actions is uncertain. In this study, we investigate the effects of high and low bone resorption on tumour growth in a mouse model of osteosclerotic metastasis. We implanted human breast cancer, MCF-7, cells into the tibiae of mice. Low and high levels of bone resorption were induced by osteoprotegerin (OPG) treatment or calcium deficient diet respectively. We demonstrate that OPG treatment significantly reduces tumour area compared to vehicle (0.42 ± 0.06 vs. 1.27 ± 0.16 mm2, P < 0.01) in association with complete inhibition of osteoclast differentiation. In contrast, low calcium diet increases tumour area compared to normal diet (0.90 ± 0.30 vs. 0.58 ± 0.20 mm2, P < 0.05) in association with increased osteoclast numbers (84.44 ± 5.18 vs. 71.11 ± 3.56 per mm2 bone lesion area, P < 0.05). Osteoblast surfaces and new woven bone formation were similarly increased within the tumour boundaries in all treatment groups. Tumour growth in this model of osteosclerotic metastasis is dependent on ongoing bone resorption, as has been observed in osteolytic models. Bone resorption, rather than bone formation, apparently mediates this effect as osteoblast surfaces in the tumour mass were unchanged by treatments. Treatment of breast cancer patients through correction of calcium deficiency and/or with anti-resorptive agents such as OPG, may improve patient outcomes in the adjuvant as well as palliative settings.
      datePublished:2008-04-18T00:00:00Z
      dateModified:2008-04-18T00:00:00Z
      pageStart:559
      pageEnd:567
      sameAs:https://doi.org/10.1007/s10585-008-9172-4
      keywords:
         Breast cancer
         Bone remodelling
         Bone metastasis
         Osteosclerosis
         Dietary calcium
         Osteoprotegerin
         Osteoclasts
         Cancer Research
         Biomedicine
         general
         Oncology
         Hematology
         Surgical Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10585-008-9172-4/MediaObjects/10585_2008_9172_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10585-008-9172-4/MediaObjects/10585_2008_9172_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10585-008-9172-4/MediaObjects/10585_2008_9172_Fig3_HTML.gif
      isPartOf:
         name:Clinical & Experimental Metastasis
         issn:
            1573-7276
            0262-0898
         volumeNumber:25
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Netherlands
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yu Zheng
            affiliation:
                  name:University of Sydney
                  address:
                     name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hong Zhou
            affiliation:
                  name:University of Sydney
                  address:
                     name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Colette Fong-Yee
            affiliation:
                  name:University of Sydney
                  address:
                     name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:James R. K. Modzelewski
            affiliation:
                  name:University of Sydney
                  address:
                     name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Markus J. Seibel
            affiliation:
                  name:University of Sydney
                  address:
                     name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Colin R. Dunstan
            affiliation:
                  name:University of Sydney
                  address:
                     name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Clinical & Experimental Metastasis
      issn:
         1573-7276
         0262-0898
      volumeNumber:25
Organization:
      name:Springer Netherlands
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Sydney
      address:
         name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
         type:PostalAddress
      name:University of Sydney
      address:
         name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
         type:PostalAddress
      name:University of Sydney
      address:
         name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
         type:PostalAddress
      name:University of Sydney
      address:
         name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
         type:PostalAddress
      name:University of Sydney
      address:
         name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
         type:PostalAddress
      name:University of Sydney
      address:
         name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yu Zheng
      affiliation:
            name:University of Sydney
            address:
               name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
               type:PostalAddress
            type:Organization
      name:Hong Zhou
      affiliation:
            name:University of Sydney
            address:
               name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
               type:PostalAddress
            type:Organization
      name:Colette Fong-Yee
      affiliation:
            name:University of Sydney
            address:
               name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
               type:PostalAddress
            type:Organization
      name:James R. K. Modzelewski
      affiliation:
            name:University of Sydney
            address:
               name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
               type:PostalAddress
            type:Organization
      name:Markus J. Seibel
      affiliation:
            name:University of Sydney
            address:
               name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
               type:PostalAddress
            type:Organization
      name:Colin R. Dunstan
      affiliation:
            name:University of Sydney
            address:
               name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
      name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
      name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
      name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
      name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
      name:Bone Research Program, ANZAC Research Institute, University of Sydney, Sydney, Australia
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(154)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.11s.

LINK . SPRINGER . COM {}